Skip to main content
Equibles
MCK logo

MCK · Mckesson Corp · Financials

Track MCK — free

Use MCK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MCK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$976.57 +14.69 (+1.53%) At close · Oct 14
S&P 500 member Russell 1000 member Rebalance outlook locked
Market Cap
$112.15B
Shares
116.59M
Volume · Oct 14 769.43K Avg daily vol (3M) 910.33K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →
Revenue
$403.43B +12.4%
FY2026 Revenue FY2008–FY2026
Net Income
$4.76B +44.5%
FY2026 Net Income FY2009–FY2026
Gross Margin
3.61% -0.1pp
FY2026 Gross Margin FY2008–FY2026
Operating Margin
1.54% +0.3pp
FY2026 Operating Margin FY2008–FY2026
Diluted EPS
$38.38 +49.2%
FY2026 Diluted EPS FY2008–FY2026
Operating Cash Flow
$6.16B +1.2%
FY2026 Operating Cash Flow FY2008–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow Adjusted All Metrics
Annual Quarterly
Line Item FY2027 (G) TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009 FY2008
— $410.98B $403.43B $359.05B $308.95B $276.71B $263.97B $238.23B $231.05B $214.32B $208.36B $198.53B $190.88B $179.05B $137.39B $122.2B $122.32B $112.08B $108.7B $106.63B $101.7B
— $396.03B $388.88B $345.73B $296.12B $264.35B $250.84B $226.08B $219.03B $202.57B $197.17B $187.26B $179.47B $167.63B $129.04B $115.32B $115.92B $106.11B $103.03B $101.25B $96.69B
— $14.96B $14.55B $13.32B $12.83B $12.36B $13.13B $12.15B $12.02B $11.75B $11.18B $11.27B $11.42B $11.41B $8.35B $6.88B $6.4B $5.97B $5.68B $5.38B $5.01B
— — 3.61% 3.71% 4.15% 4.47% 4.97% 5.1% 5.2% 5.48% 5.37% 5.68% 5.98% 6.37% 6.08% 5.63% 5.23% 5.33% 5.22% 5.04% 4.93%
— — — — — — — — $96M $71M $125M $341M $392M $392M $457M $433M $402M $407M $376M $364M $347M
— — — — — — — — — — — — — — — $805M $764M $767M — — —
— — — — — — — — — — — — — — — $2.35B $2.07B $1.84B $1.68B $1.64B $1.56B
— $8.16B $8.1B $8.51B $8.66B $7.78B $10.54B $8.85B $9.18B $8.44B $8.14B $7.45B $7.38B $7.9B $5.39B $4.11B $3.73B — — — —
— $300M $276M $226M $249M $236M $332M $422M $462M $485M $503M $444M $431M $494M $319M $215M $191M $132M — — —
— $325M $287M $272M $279M $272M $312M $344M $335M $317M $951M $910M $885M $1.02B $735M $581M $493M $496M $477M $313M —
— $334M $245M $344M $115M $209M $245M $219M $156M $352M $13M $14M $229M — — — — — — — —
— $8.46B $8.34B $8.9B $8.92B $7.98B $11.09B $17.19B $9.53B $10.87B $10.42B $4.15B $7.87B $8.44B $5.91B $4.53B $4.28B $4.15B $3.67B $4.18B $3.53B
— $6.5B $6.21B $4.42B $3.91B $4.38B $2.04B -$5.04B $2.49B $886M $762M $7.12B $3.55B $2.97B $2.44B $2.35B $2.12B $1.82B $2.01B $1.2B $1.48B
— — 1.54% 1.23% 1.27% 1.58% 0.77% -2.12% 1.08% 0.41% 0.37% 3.59% 1.86% 1.66% 1.78% 1.92% 1.74% 1.62% 1.85% 1.12% 1.45%
— $6.82B $6.5B $4.69B $4.19B $4.65B $2.35B -$4.7B $2.82B $1.2B $1.71B $8.03B $4.43B $3.99B $3.17B $2.93B $2.62B $2.32B $2.49B $1.51B —
— $275M $247M $265M $252M $248M $178M $217M $249M $264M $283M — — — — — — — — — —
— — $179M $173M $118M $107M $10M $12M $49M $39M $48M $29M $18M $20M $16M $22M $19M $18M $16M $31M —
— $238M $236M $202M $132M $497M $259M $223M $12M $182M $130M $77M $58M $63M $32M $34M $20M $36M $43M $12M $121M
— — $7M $9M $4M $5M $43M $48M $36M $43M $32M $30M $15M $12M $0 $3M $9M -$6M $6M $7M —
— $6.46B $6.2B $4.36B $3.79B $4.63B $1.93B -$5.03B $1.14B $610M $239M $6.89B $3.25B $2.66B $2.17B $1.95B $1.89B $1.64B $1.86B $1.06B —
— $1.16B $1.1B $878M $629M $905M $636M -$695M $18M $356M -$53M $1.61B $908M $815M $757M $587M $514M $505M $601M $241M $468M
— $4.59B $4.76B $3.3B $3B $3.56B $1.11B -$4.54B $900M $34M $67M $5.07B $2.26B $1.48B $1.26B $1.34B $1.4B $1.2B $1.26B $823M —
— — 1.18% 0.92% 0.97% 1.29% 0.42% -1.91% 0.39% 0.02% 0.03% 2.55% 1.18% 0.82% 0.92% 1.09% 1.15% 1.07% 1.16% 0.77% —
— $708M $337M $186M $158M $162M $173M $199M $220M $221M $230M $83M $52M $67M -$5M $0 $0 — — — —
— — — — — — — — — — — — — — — — — $1.2B $1.26B $823M $990M
— $4.74B $4.95B $3.24B $3.03B $4.19B $1.23B -$4.32B $1.05B -$98M $491M $4.49B $2.41B -$234M $1.33B $1.27B $1.32B $1.28B $1.45B — —
USD/shares — $37.44 $38.55 $25.86 $22.54 $25.23 $7.32 -$28.26 $4.98 $0.17 $0.32 $22.95 $9.82 $6.37 $5.51 $5.71 $5.70 $4.65 $4.70 $2.99 $3.40
USD/shares $44.20 – $45.00* $37.28 $38.38 $25.72G $22.39G $25.03G $7.23G -$28.26G $4.95 $0.17 $0.32 $22.73 $9.70 $6.27 $5.41 $5.59 $5.59 $4.57 $4.62 $2.95 $3.32
shares — — 123.6M 127.4M 133.2M 141.1M 152.3M 160.6M 180.6M 196.3M 208M 221M 230M 232M 229M 235M 246M 258M 269M 275M 291M
shares — — 124.1M 128.1M 134.1M 142.2M 154.1M 160.6M 181.6M 197.3M 209M 223M 233M 235M 233M 239M 251M 263M 273M 279M 298M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2008–FY2026: $34.06B in buybacks, $4.55B in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-06-30 USD 292,000,000 10-Q filed 2026-08-05
Debt and lease obligations 2026-06-30 USD 9,700,000,000 10-Q filed 2026-08-05
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current long-term debt and lease obligations
USD 1,297,000,000
Long-term debt, including current maturities
USD 9,729,000,000
Noncurrent long-term debt and lease obligations
USD 8,432,000,000
Noncurrent operating lease liabilities 2026-06-30 USD 1,680,000,000 10-Q filed 2026-08-05
9 filing observations remain unmatched and are excluded from instrument histories.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Some debt data could not be processed yet.
6 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.

Covenants

Some sections could not be verified in 1 agreement document. Other restrictions or tests may apply.

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

0.900% Notes due 2025

Note · McKesson Corporation

Reference: 0.900% Notes due 2025

Active
Original principal
USD 500,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 0.9% Reported 2020-12-03 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2020-12-03 Original principal USD 500,000,000 Exact source document Parent 8-K filing · 2020-12-03
    On November 30, 2020, McKesson Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $500,000,000 aggregate principal amount of its 0.900% Notes due 2025 (the “Notes”). On December 3, 2020, the Notes were issued pursuant to the Indenture, dated as of December 4, 2012 (the “Indenture”) between the Company and Wells Fargo Bank, National Association, as trustee (the “Trustee”), as supplemented by an Officer’s Certificate, dated as of December 3, 2020, setting forth certain terms of the Notes (the “Officer’s Certificate”).
    Issuer evidence: On November 30, 2020, McKesson Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $500,000,000 aggregate principal amount of its 0.900% Notes due 2025 (the “Notes”). On December 3, 2020, the Notes were issued pursuant to the Indenture, dated as of December 4, 2012 (the “Indenture”) between the Company and Wells Fargo Bank, National Association, as trustee (the “Trustee”), as supplemented by an Officer’s Certificate, dated as of December 3, 2020, setting forth certain terms of the Notes (the “Officer’s Certificate”).
    Supporting evidence: On November 30, 2020, McKesson Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $500,000,000 aggregate principal amount of its 0.900% Notes due 2025 (the “Notes”).
    Supporting evidence: On November 30, 2020, McKesson Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $500,000,000 aggregate principal amount of its 0.900% Notes due 2025 (the “Notes”).

4.250% Notes due 2029

Note · McKesson Corporation

Reference: 4.250% Notes due 2029

Active
Original principal
USD 500,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 4.25% Reported 2024-09-10 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2024-09-10 Original principal USD 500,000,000 Exact source document Parent 8-K filing · 2024-09-10
    On September 5, 2024, McKesson Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell $500,000,000 aggregate principal amount of its 4.250% Notes due 2029 (the “Notes”). On September 10, 2024, the Notes were issued pursuant to the Indenture, dated February 15, 2023 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as amended and supplemented by an Officer’s Certificate, dated September 10, 2024, setting forth certain terms of the Notes (the “Officer’s Certificate”).
    Issuer evidence: On September 5, 2024, McKesson Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell $500,000,000 aggregate principal amount of its 4.250% Notes due 2029 (the “Notes”). On September 10, 2024, the Notes were issued pursuant to the Indenture, dated February 15, 2023 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as amended and supplemented by an Officer’s Certificate, dated September 10, 2024, setting forth certain terms of the Notes (the “Officer’s Certificate”).
    Supporting evidence: On September 5, 2024, McKesson Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell $500,000,000 aggregate principal amount of its 4.250% Notes due 2029 (the “Notes”). On September 10, 2024, the Notes were issued pursuant to the Indenture, dated February 15, 2023 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as amended and supplemented by an Officer’s Certificate, dated September 10, 2024, setting forth certain terms of the Notes (the “Officer’s Certificate”).
    Supporting evidence: On September 5, 2024, McKesson Corporation (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell $500,000,000 aggregate principal amount of its 4.250% Notes due 2029 (the “Notes”). On September 10, 2024, the Notes were issued pursuant to the Indenture, dated February 15, 2023 (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as amended and supplemented by an Officer’s Certificate, dated September 10, 2024, setting forth certain terms of the Notes (the “Officer’s Certificate”).

5.250% Notes due 2026

Note · McKesson Corporation

Reference: 5.250% Notes due 2026

Active
Original principal
USD 500,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Last reported interest terms: 5.25% Reported 2023-02-15 Later filings may not restate these terms; this does not confirm they still apply.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2023-02-15 Original principal USD 500,000,000 Exact source document Parent 8-K filing · 2023-02-15
    On February 13, 2023, McKesson Corporation (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with the several underwriters named therein (the "Underwriters"), pursuant to which the Company agreed to issue and sell $500,000,000 aggregate principal amount of its 5.250% Notes due 2026 (the "Notes"). On February 15, 2023, the Notes were issued pursuant to the Indenture, dated February 15, 2023, between the Company and U.S. Bank Trust Company, National Association, as trustee (the "Trustee"), as supplemented by an Officer's Certificate, dated February 15, 2023, setting forth certain terms of the Notes (the "Officer's Certificate").
    Issuer evidence: On February 13, 2023, McKesson Corporation (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with the several underwriters named therein (the "Underwriters"), pursuant to which the Company agreed to issue and sell $500,000,000 aggregate principal amount of its 5.250% Notes due 2026 (the "Notes"). On February 15, 2023, the Notes were issued pursuant to the Indenture, dated February 15, 2023, between the Company and U.S. Bank Trust Company, National Association, as trustee (the "Trustee"), as supplemented by an Officer's Certificate, dated February 15, 2023, setting forth certain terms of the Notes (the "Officer's Certificate").
    Supporting evidence: The Notes will bear interest at the rate of 5.250% per year. Interest on the Notes is payable on February 15 and August 15 of each year, beginning on August 15, 2023.
    Supporting evidence: On February 13, 2023, McKesson Corporation (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with the several underwriters named therein (the "Underwriters"), pursuant to which the Company agreed to issue and sell $500,000,000 aggregate principal amount of its 5.250% Notes due 2026 (the "Notes"). On February 15, 2023, the Notes were issued pursuant to the Indenture, dated February 15, 2023, between the Company and U.S. Bank Trust Company, National Association, as trustee (the "Trustee"), as supplemented by an Officer's Certificate, dated February 15, 2023, setting forth certain terms of the Notes (the "Officer's Certificate").
    Supporting evidence: On February 13, 2023, McKesson Corporation (the "Company") entered into an Underwriting Agreement (the "Underwriting Agreement") with the several underwriters named therein (the "Underwriters"), pursuant to which the Company agreed to issue and sell $500,000,000 aggregate principal amount of its 5.250% Notes due 2026 (the "Notes"). On February 15, 2023, the Notes were issued pursuant to the Indenture, dated February 15, 2023, between the Company and U.S. Bank Trust Company, National Association, as trustee (the "Trustee"), as supplemented by an Officer's Certificate, dated February 15, 2023, setting forth certain terms of the Notes (the "Officer's Certificate").

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
0.28×
Medical Distribution median 0.86×
EV/EBIT
17.96×
P/E (TTM)
25.80×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
North American Pharmaceutical Segment $336,652,000,000 $304,507,000,000 $261,368,000,000 — — — — —
Oncology and Multispecialty Segment $48,423,000,000 $36,862,000,000 $30,490,000,000 — — — — —
Medical Surgical Solutions Segment $11,507,000,000 $11,380,000,000 $11,309,000,000 $11,110,000,000 $11,608,000,000 $10,099,000,000 $8,305,000,000 $7,618,000,000
Prescription Technology Solutions Segment $5,805,000,000 $5,216,000,000 $4,769,000,000 $4,387,000,000 $3,864,000,000 $2,890,000,000 $2,705,000,000 $2,489,000,000
International Segment — — — $20,598,000,000 $36,345,000,000 $35,965,000,000 $38,341,000,000 $38,023,000,000
US Pharmaceutical Segment — — — $240,616,000,000 $212,149,000,000 $189,274,000,000 $181,700,000,000 $166,189,000,000

By Geography (USD)

Component FY2020 FY2019 FY2018
United States $192,709,000,000 $176,296,000,000 $169,943,000,000
Non Us $38,342,000,000 $38,023,000,000 $38,414,000,000
Key facts CIK 927653 CUSIP 58155Q103 13F (30d) 205 filings 175 filers Visit website Investor relations